Jane K. Stock

发表

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Lale Tokgözoğlu, Ian Graham, Stephen J. Nicholls, 2017, European heart journal.

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

J. Borén, D. Gaudet, M. Taskinen, 2021, European heart journal.

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

H. Ginsberg, Jane K. Stock, M. Chapman, 2015, Current opinion in lipidology.

HDL function and cardiovascular risk: debate continues...

Jane K. Stock, 2013, Atherosclerosis.

Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods.

Jane K. Stock, 2014, Atherosclerosis.

Controversies in dyslipidaemia management.

Jane K. Stock, 2012, Atherosclerosis.

The emerging role of lipidomics.

Jane K. Stock, 2012, Atherosclerosis.

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Jeroen J. Bax, J. Borén, D. Grobbee, 2017, European heart journal.

EAS 2017 Congress Prague highlights.

Jane K. Stock, 2017, Atherosclerosis.

Triglycerides and cardiovascular risk: Apolipoprotein B holds the key.

Jane K. Stock, 2019, Atherosclerosis.

PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads.

L. Annemans, Jane K. Stock, M. Chapman, 2019, Journal of clinical lipidology.

Cholesterol and inflammatory risk: Insights from secondary and primary prevention.

Jane K. Stock, 2019, Atherosclerosis.

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement.

F. Kronenberg, J. Borén, A. von Eckardstein, 2020, The lancet. Diabetes & endocrinology.

Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?

Jane K. Stock, 2013, Atherosclerosis.

Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel.

Jane K. Stock, 2015, Atherosclerosis.

Targeting LDL cholesterol: Early treatment is key to population health.

Jane K. Stock, 2020, Atherosclerosis.

News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.

Jane K. Stock, 2019, Atherosclerosis.

Latest European Atherosclerosis Society statement reaffirms commitment to the UN Sustainable Development Goals 2030 Agenda.

Jane K. Stock, 2021, Atherosclerosis.

Familial hypercholesterolemia: An urgent public health priority.

Jane K. Stock, 2020, Atherosclerosis.

First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.

Jane K. Stock, 2019, Atherosclerosis.

Highlights from the 87th EAS congress, 26-29th May 2019.

Jane K. Stock, 2019, Atherosclerosis.

EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients.

Jane K. Stock, 2021, Atherosclerosis.

Joint statement from the European Atherosclerosis Society and European Society of Vascular Medicine focuses on patients with peripheral arterial disease.

Jane K. Stock, 2021, Atherosclerosis.

Mediterranean diet for combating the metabolic syndrome.

Jane K. Stock, 2011, Atherosclerosis.

Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.

Jane K. Stock, 2022, Atherosclerosis.

Novel insights into lipoprotein(a): News from Atherosclerosis.

Jane K. Stock, 2022, Atherosclerosis.

Not at LDL cholesterol goal? Consider statin responsiveness.

Jane K. Stock, 2016, Atherosclerosis.

Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?

Jane K. Stock, 2020, Atherosclerosis.

Commentary on rare dyslipidaemia paper.

Jane K. Stock, 2019, Atherosclerosis.

EAS Consensus Panel statement on homozygous FH.

Jane K. Stock, 2015, Atherosclerosis.

Improving the care of high-risk patients: the potential of PCSK9.

Jane K. Stock, 2014, Atherosclerosis.

News from the literature: focus on joint ESC/EAS dyslipidemia guidelines.

Jane K. Stock, 2012, Atherosclerosis.

New joint consensus initiative on quantifying atherogenic lipoproteins.

Jane K. Stock, 2018, Atherosclerosis.

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

F. Kronenberg, A. von Eckardstein, M. Koschinsky, 2022, European heart journal.

Novel therapeutics specific to lipoprotein(a).

Jane K. Stock, 2019, Atherosclerosis.

Residual inflammatory risk: Lessons from trials for the future.

Jane K. Stock, 2020, Atherosclerosis.

Navigating the highlights of EAS Congress Lisbon.

Jane K. Stock, 2018, Atherosclerosis.

New studies in atherosclerosis research.

Jane K. Stock, 2011, Atherosclerosis.

DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe.

Jane K. Stock, 2020, Atherosclerosis.

New EAS Consensus Statement on FH: improving the care of FH patients.

Jane K. Stock, 2013, Atherosclerosis.

CETP inhibition in perspective.

Jane K. Stock, 2012, Atherosclerosis.

Importance of HDL functionality to cardiovascular risk.

Jane K. Stock, 2011, Atherosclerosis.

Should we treat high LDL cholesterol in 'healthy' elderly individuals?

Jane K. Stock, 2020, Atherosclerosis.

Low-density lipoproteins cause atherosclerotic cardiovascular disease

R. Krauss, J. Borén, H. Schunkert, 2018 .

SAMSON, SAMS and nocebo effects.

Jane K. Stock, 2021, Atherosclerosis.

New prospects for PCSK9 inhibition?

Jeroen J. Bax, J. Borén, D. Grobbee, 2018, European heart journal.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

P. Libby, P. Ridker, J. Després, 2019, Cardiovascular Diabetology.

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.

W. März, M. Banach, J. Zamorano, 2021, Atherosclerosis.

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Lawrence A Leiter, R. Krauss, W. März, 2018, European heart journal.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

Nikolaus Marx, Takashi Kadowaki, Alberto Zambon, 2008, The American journal of cardiology.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

F. Sacks, P. Zimmet, C. Wanner, 2008, Diabetes & vascular disease research.

patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic

F. Sacks, P. Zimmet, C. Wanner, 2011 .

Do current criteria for 'healthy BMI' in adolescence warrant a re-think?

Jane K. Stock, 2011, Atherosclerosis.

Gut microbiota: an environmental risk factor for cardiovascular disease.

Jane K. Stock, 2013, Atherosclerosis.

Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group.

Jane K. Stock, Jane Stock, 2015, Atherosclerosis.

Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.

F. Kronenberg, M. Koschinsky, G. Watts, 2023, Atherosclerosis.

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

D. Gaudet, R. Hegele, F. Raal, 2023, European heart journal.

The challenge of peripheral arterial disease: How do we improve outcome?

Jane K. Stock, 2018, Atherosclerosis.

Adverse effects of statin therapy: perception vs. the evidence - focus on glucose cognitive, and hepatic function, and

R. Krauss, P. Thompson, R. Hegele, 2018 .

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

M. Gulati, M. Kavousi, M. Benn, 2023, European heart journal.

Highlights of the 83rd European Atherosclerosis Society (EAS) annual Congress, Glasgow 22-25 March, 2015.

Jane K. Stock, 2015, Atherosclerosis.

EAS Consensus Panel statement on homozygous FH.

Jane K. Stock, 2015, Atherosclerosis.

HDL markers in cardiovascular risk prediction: Ethnicity matters.

Jane K. Stock, 2020, Atherosclerosis.

Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Jeroen J. Bax, J. Borén, D. Grobbee, 2017, European heart journal.